1,486 results match your criteria Expert Review of Clinical Immunology[Journal]


The molecular immunology of human susceptibility to fungal diseases: lessons from single gene defects of immunity.

Authors:
Donald C Vinh

Expert Rev Clin Immunol 2019 Feb 18. Epub 2019 Feb 18.

a Director, Infectious Disease Susceptibility Program, Associate Professor, FRQS Clinician-Scientist, Dept of Medicine (Division of Infect ious Diseases; Division of Allergy & Clinical Immunology), Dept of Medical Microbiology; Dept of Human Genetics , McGill University Health Centre - Research Institute , 1001 Decarie Blvd; Block E; Rm EM3-3230 (Mail Drop: EM3-3211), Montreal , Quebec , Canada H4A 3J1 , Ph (office); x42811 (admin assist); Fax. Email:

Introduction: Fungal diseases are a threat to human health. Therapies targeting the fungus continue to lead to disappointing results. Strategies targeting the host response represent unexplored opportunities for innovative treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1584038DOI Listing
February 2019

The importance of early peanut ingestion in the prevention of peanut allergy.

Expert Rev Clin Immunol 2019 Feb 14. Epub 2019 Feb 14.

a Jaffe Food Allergy Institute, Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai , One Gustave Levy Pl, New York , NY 10128 , USA.

Introduction: Peanut allergy appears to have increased in prevalence, is often severe and is typically life-long. Therefore, reducing its incidence through a primary prevention strategy is a priority. Guidelines on peanut introduction have evolved with time and given evidence of peanut allergy risk reduction with early infant ingestion exposure, the current US advice promotes early introduction for infants, particularly targeting those at highest risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1582331DOI Listing
February 2019

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018.

Expert Rev Clin Immunol 2019 Feb 14:1-17. Epub 2019 Feb 14.

a Division of Research , Matrix45 , Tucson , AZ , USA.

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008-2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1574571DOI Listing
February 2019

Abatacept for the treatment of rheumatoid arthritis.

Expert Rev Clin Immunol 2019 Feb 7:1-8. Epub 2019 Feb 7.

b Fundacion Ramon Dominguez, Hospital Clinico Universitario , Santiago de Compostela , Spain.

Introduction: Rheumatoid arthritis (RA) is a complex disease in which different mechanisms are involved. Studies suggest a key role for aberrant pathways of T-cell activation in the initiation and perpetuation of disease. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin G1 (IgG1) fused to the extracellular domain of cytotoxic T lymphocyte-associated antigen (CTLA4). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1579642DOI Listing
February 2019
3 Reads

Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development.

Expert Rev Clin Immunol 2019 Feb 7:1-4. Epub 2019 Feb 7.

a Department of Rheumatology and Clinical Immunology , University Medical Center Utrecht , Utrecht , The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1580144DOI Listing
February 2019
1 Read

Screening children for eosinophilic esophagitis: allergic and other risk factors.

Expert Rev Clin Immunol 2019 Feb 5. Epub 2019 Feb 5.

a Children's Hospital of Philadelphia , Division of Allergy & Immunology , Philadelphia , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1579643DOI Listing
February 2019

Measuring and managing appearance anxiety in patients with systemic sclerosis.

Expert Rev Clin Immunol 2019 Jan 25:1-6. Epub 2019 Jan 25.

b Department of Psychology , San Diego State University , San Diego , CA , USA.

Introduction: Systemic sclerosis (SSc, scleroderma) is a progressive, autoimmune, connective tissue disease of unknown etiology that can cause changes in appearance in socially important areas of the body (e.g. face and hands). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1573673DOI Listing
January 2019
1 Read

CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives.

Expert Rev Clin Immunol 2019 Jan 25:1-12. Epub 2019 Jan 25.

a Department of Immunology, Institute of Biomedical Sciences , University of São Paulo , São Paulo , Brazil.

Introduction: CD40 ligand (CD40L) deficiency or X-linked Hyper-IgM syndrome is a severe primary immunodeficiency caused by mutations in the CD40L gene. Despite currently available treatments, CD40L-deficient patients remain susceptible to life-threatening infections and have poor long term survival. Areas covered: Here, we discuss clinical and immunological characteristics of CD40L deficiency as well as current therapeutic strategies used for patient management. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1573674DOI Listing
January 2019
5 Reads

B-cell depleting immunotherapies: therapeutic opportunities and toxicities.

Expert Rev Clin Immunol 2019 Feb 6:1-13. Epub 2019 Feb 6.

a Department of Pediatric Hematology and Oncology, Cellular and Gene Therapy , IRCCS Ospedale Pediatrico Bambino Gesù , Rome , Italy.

Introduction: The last few years have witnessed what can certainly be defined as a 'period of renaissance' for immunotherapy in the field of hematological malignancies. In particular, antibody-mediated and cell-mediated immunotherapy have significantly changed the treatment approach of patients with B-cell lymphoproliferative disorders. These therapies, initially employed in patients with refractory/relapsed disease, are now integrated in the treatment of newly diagnosed patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1573672DOI Listing
February 2019
1 Read

Belatacept in kidney transplantation and its limitations.

Expert Rev Clin Immunol 2019 Jan 24:1-9. Epub 2019 Jan 24.

a Service de Néphrologie, Hémodialyse , Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes , Grenoble , France.

Introduction: Since the approval of belatacept in 2011 for use in the setting of de novo kidney transplantation, this CD80/86 - CD28 co-stimulation blocker has been shown to be a valuable treatment option for maintenance immunosuppression. Areas covered: In this setting, belatacept has been associated with superior glomerular filtration rate as compared to calcineurin inhibitor-based treatments because of the absence of nephrotoxicity. Additionally, belatacept avoids the cardiovascular side effects (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1574570DOI Listing
January 2019
1 Read

Diagnosing autoimmune encephalitis based on clinical features and autoantibody findings.

Authors:
Christian G Bien

Expert Rev Clin Immunol 2019 Jan 24. Epub 2019 Jan 24.

a Epilepsy Center Bethel, Krankenhaus Mara , Maraweg 17-21 33617 Bielefeld , Germany.

Introduction: Autoimmune encephalitides have been accepted as a reproducible and treatable new group of diseases. At present, there is concern that such diagnoses might be made too liberally. Areas covered: This article suggests how to make valid diagnoses. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1573676DOI Listing
January 2019
2 Reads

Pain and affective distress in arthritis: relationship to immunity and inflammation.

Expert Rev Clin Immunol 2019 Jan 23:1-12. Epub 2019 Jan 23.

b Lawson Health Research Institute , London , Ontario , Canada.

Introduction: Most arthritides are associated with pain and psychological distress (clinically significant depression and anxiety). Pain and depression are mutually exacerbating; both may continue even when joint involvement appears well controlled. Area covered: There is strong evidence that arthritis-related stress impacts the central nervous system and, together with peripheral inflammatory changes, can cause central sensitization that can lead to chronic pain and worsening of affective distress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1573675DOI Listing
January 2019
1 Read

Canakinumab for the treatment of hyperimmunoglobulin D syndrome.

Expert Rev Clin Immunol 2019 Mar 26;15(3):215-220. Epub 2019 Jan 26.

b Pediatric Rheumatology Unit, Pediatrics Department, Hospital Sant Joan de Déu , Universitat de Barcelona , Barcelona , Spain.

Introduction: Mevalonate Kinase Deficiency (MKD) is a rare monogenic autoinflammatory disorder (AID) with autosomal recessive inheritance caused by mutations in the MVK gene. It includes hyperimmunoglobulinemia D syndrome (HIDS) and mevalonic aciduria (a severe form). Patients have recurrent inflammatory attacks with high fever, gastrointestinal symptoms, lymphadenopathy, splenomegaly, arthralgia, rash, pharyngitis, aphtosis and constitutional complaints. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1571410DOI Listing
March 2019
6 Reads

B cells and atherosclerosis in systemic lupus erythematosus.

Expert Rev Clin Immunol 2019 Jan 17:1-13. Epub 2019 Jan 17.

a Department of Physiology, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Cardiovascular (CV) events, as a result of accelerated atherosclerosis, are an important cause of mortality in patients with Systemic lupus erythematosus (SLE). The etiology of SLE is multifactorial and still unclear; among other potential culprits, excessive B cell activation seems to play a crucial role. Accumulating evidence supports a contributory role of B cells in the pathogenesis of atherosclerosis as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1571411DOI Listing
January 2019
2 Reads

Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis.

Expert Rev Clin Immunol 2019 Jan 11:1-15. Epub 2019 Jan 11.

a Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases , ICMiD, Hospital Clínic , Barcelona , Spain.

Introduction: Sarcoidosis is a complex systemic disease with a silent, long-term evolution, and a heterogeneous clinical presentation. The diagnostic approach is complex with no single diagnostic test that may confirm the disease. Areas covered: A large list of serum biomarkers has been tested during the last 40 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1568240DOI Listing
January 2019
9 Reads

Epidemiology, characterization and diagnosis of neuropsychiatric events in systemic lupus erythematosus.

Expert Rev Clin Immunol 2019 Jan 11. Epub 2019 Jan 11.

b Laboratory of Autoimmune Diseases, School of Medical Science , University of Campinas , Campinas , SP 13083-872 , Brazil.

Introduction: Neuropsychiatric systemic lupus erythematosus (NPSLE) is characterized by a heterogeneity of clinical manifestations. The absence of diagnostic criteria and the lack of clinical trials is a challenge in clinical practice. Areas covered: A literature review was performed to describe epidemiology, characterization (clinical, immunological and imaging), diagnosis and treatment of NPSLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564040DOI Listing
January 2019
2 Reads

Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness.

Expert Rev Clin Immunol 2019 Mar 4;15(3):241-250. Epub 2019 Feb 4.

e Cumming School of Medicine , University of Calgary , Calgary , Canada.

Introduction: Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of ANA associated rheumatic diseases. Areas covered: This review aims to analyze and interpret the current published knowledge and recent findings to provide guidance in the use of anti-DFS70 antibodies to analyze associations of this unique autoantibody. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1562903DOI Listing
March 2019
10 Reads

Management of pregnant women with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Jan 8. Epub 2019 Jan 8.

a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Via Giustiniani, 2, 35128 Padua , Italy.

Introduction: Important advancements in pregnancy outcome have been reported in women with antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL related pregnancy morbidity is not guided by consistent findings from well-designed trials. Areas covered: The current study draws a picture of the studies in the literature by performing a Medline search of relevant English language articles and reports our experience in managing different subsets of obstetric antiphospholipid syndrome (APS), defined on the basis of their clinical and laboratory characteristics. The management of pregnant women with non-criteria APS manifestations and that of aPL carriers during their first pregnancy is also examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1565995DOI Listing
January 2019
2 Reads

Exercise-induced anaphylaxis: causes, consequences, and management recommendations.

Expert Rev Clin Immunol 2019 Mar 9;15(3):265-273. Epub 2019 Jan 9.

a Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA) , Odense University Hospital , Odense , Denmark.

Introduction: Exercise-induced anaphylaxis (EIA) denotes a range of disorders where anaphylaxis occurs in relation to physical exercise. Typical symptoms include flushing, pruritus, urticaria, angioedema, respiratory symptoms, gastrointestinal symptoms, hypotension, and collapse during or after exercise. The far best described entity within EIA is food-dependent exercise-induced anaphylaxis (FDEIA), where symptoms only occur in combination with food intake. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562904DOI Listing
March 2019
6 Reads

The Immunomodulatory Role of Interleukin-35 in Fibrotic Diseases.

Expert Rev Clin Immunol 2018 Dec 27. Epub 2018 Dec 27.

d Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine , University of Alabama at Birmingham , Birmingham , AL , USA.

Introduction: Fibrosis makes numerous diseases in all organs more complicated and leads to severe consequences in the lung, liver, heart, kidney and skin. In essence, fibrosis results from excessive, persistent and oftentimes nonreversible aggregation of extracellular matrix (ECM) or simply as collagen during the process of tissue injury and repair. Recent studies suggest the pathology of fibrosis, especially in pulmonary and liver fibrosis, involves various types of immune cells and soluble mediators including interleukin (IL)-35, a recently identified heterodimeric cytokine that belongs to the IL-12 cytokine family. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564041DOI Listing
December 2018
2 Reads
3.342 Impact Factor

Ixekizumab for the treatment of psoriasis: an update on new data since first approval.

Expert Rev Clin Immunol 2018 Dec 27:1-11. Epub 2018 Dec 27.

a Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev and Gentofte Hospital , University of Copenhagen , Hellerup , Denmark.

Introduction: Psoriasis is a chronic immune-mediated skin disease with a multifactorial etiology. Studies have shown that the inflammatory cytokine interleukin-17A (IL-17A) is a key mediator in the pathogenesis. Targeted biologics have changed the outcome for patients in a variety of diseases including psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1559730DOI Listing
December 2018
2 Reads

Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.

Expert Rev Clin Immunol 2019 Mar 27;15(3):211-213. Epub 2018 Dec 27.

a Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1559731DOI Listing
March 2019
1 Read

Topical agents for the treatment of atopic dermatitis.

Expert Rev Clin Immunol 2018 Dec 27. Epub 2018 Dec 27.

a Department of Dermatology , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Introduction: Atopic dermatitis (AD) is perhaps the most common inflammatory skin disorder worldwide, with an increasing incidence in developed countries. The mainstay treatment for patients with AD are topical therapies, which are used not only by the mild patients, but also by the moderate-to-severe patients, in conjunction with systemic treatment. While topical steroids and calcineurin antagonists are widely used, these are associated with long-term cutaneous adverse effects (AEs) or a black box warning, preventing their chronic use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564038DOI Listing
December 2018
1 Read

Association of TNF, IL12, and IL23 gene polymorphisms and psoriatic arthritis: meta-analysis.

Expert Rev Clin Immunol 2019 Mar 24;15(3):303-313. Epub 2019 Jan 24.

a Postgraduate Program in Biosciences and Physiopathology, Department of Clinical Analysis and Biomedicine , Maringá State University , Maringá , Brazil.

Background: Psoriatic arthritis (PsA) is a chronic skin and joint condition that considerably affects patient quality of life. Several studies have demonstrated different associations of genetic polymorphisms in the pathogenic process of PsA. Therefore, we conducted a meta-analysis to estimate the effect of polymorphisms in the cytokines TNF, IL12B, IL23A, and IL23R on PsA risk. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1564039DOI Listing
March 2019
13 Reads

Infusion-related reactions to rituximab: frequency, mechanisms and predictors.

Expert Rev Clin Immunol 2018 Dec 24. Epub 2018 Dec 24.

a Département d'Hématologie Clinique , CHRU de Montpellier , Montpellier , France.

Introduction: Rituximab, an anti-CD20 monoclonal antibody (mAb), is indicated in the treatment of B-cell non Hodgkin lymphomas, chronic lymphoid leukemia and rheumatoid arthritis. The occurrence of infusion related reactions (IRR), especially during the first infusion, is one of the main concerns of rituximab, otherwise well tolerated. Although IRR are usually mild to moderate, fatal evolutions have been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562905DOI Listing
December 2018
2 Reads

Atopic dermatitis: a review of evolving targeted therapies.

Expert Rev Clin Immunol 2019 Mar 14;15(3):275-288. Epub 2019 Jan 14.

a Department of Internal Medicine , University of North Dakota School of Medicine and Health Sciences , Bismarck , ND , USA.

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin condition, affecting a significant number of patients of all ages. As we learn more about the pathogenesis of AD, new targeted treatment options are being developed to better tailor its management. Currently, a variety of biologic agents are utilized to target specific components and regulators of the inflammatory pathways in allergic and inflammatory conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1560267DOI Listing
March 2019
2 Reads

The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Expert Rev Clin Immunol 2019 Feb 8;15(2):123-134. Epub 2019 Jan 8.

a NIHR Leeds Biomedical Research Centre , Leeds Teaching Hospitals NHS Trust , Leeds , UK.

Introduction: Secukinumab, an interleukin-17A (IL-17A) antagonist, is the first non-TNF alpha inhibitor agent licensed for ankylosing spondylitis (AS), which opens up a new era of alternative cytokine targets beyond TNF. Areas covered: This review explores the pathophysiology and scientific evidence behind the use of this new mode of action and discusses the basis for its efficacy and clinical utility in the management of AS. In particular, how the emergent data points towards the efficacy of secukinumab and ixekizumab, a second emergent IL-17A blocker, in AS has helped focus research into the IL-23/17 axis in entheseal driven disease in man and how IL-17A inhibition may be linked to the presence of innate and adaptive immune cell populations capable of IL-17A elaboration in these target tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1561281DOI Listing
February 2019
3 Reads

New frontiers in precision medicine for sepsis-induced immunoparalysis.

Expert Rev Clin Immunol 2019 Mar 7;15(3):251-263. Epub 2019 Jan 7.

a Department of Intensive Care Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.

Introduction: In the last decade, the sepsis research field has shifted focus from targeting hyperinflammation to reversing sepsis-induced immunoparalysis. Sepsis-induced immunoparalysis is very heterogeneous: the magnitude and the nature of the underlying immune defects differ considerably between patients, but also within individuals over time. Therefore, a 'one-treatment-fits-all' strategy for sepsis-induced immunoparalysis is bound to fail, and an individualized 'precision medicine' approach is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562336DOI Listing
March 2019
6 Reads

New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.

Expert Rev Clin Immunol 2019 Mar 2;15(3):289-301. Epub 2019 Jan 2.

a Department of Biochemical and Clinical Diagnostic , IRCCS SDN , Naples , Italy.

Introduction: High-resolution imaging is the gold standard to measure the functional and biological features of bone lesions. Imaging markers have allowed the characterization both of tumour heterogeneity and metabolic data. Besides, ongoing studies are evaluating a combined use of 'imaging markers', such as SUVs, MATV, TLG, ADC from PET and MRI techniques respectively, and several 'biomarkers' spanning from chemokine immune-modulators, such as PD-1, RANK/RANKL, CXCR4/CXCL12 to transcription factors, such as TP53, RB1, MDM2, RUNX family, EZH2, YY1, MAD2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1561283DOI Listing
March 2019
1 Read

From mother to baby: antenatal exposure to monoclonal antibody biologics.

Expert Rev Clin Immunol 2019 Mar 24;15(3):221-229. Epub 2019 Jan 24.

i Departments of Pediatrics and Community Health & Epidemiology , Dalhousie University , Halifax , NS , Canada.

Introduction: More women with autoimmune and inflammatory conditions are being treated with monoclonal antibody biologics (mAbs) during their pregnancy, to maintain clinical remission. The use of anti-tumor necrosis factor alpha agents in pregnancy appears to be safe but less is known regarding other mAbs, such as anti-integrins and anti-cytokine agents. There are currently no comprehensive guidelines on how to manage the exposed infants. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1561282DOI Listing
March 2019
14 Reads

New insights into the pathophysiology of IgG4-related disease and markers of disease activity.

Expert Rev Clin Immunol 2019 Mar 27;15(3):231-239. Epub 2018 Dec 27.

a Division of Rheumatology, Department of Internal Medicine , Kanazawa University Graduate School of Medicine , Kanazawa , Japan.

Introduction: Recently, IgG4-related disease (IgG4-RD) has become a well-recognized clinical entity, although its causes are still not well understood. The pathophysiology of IgG4-RD has been reported from a variety of aspects. Areas covered: In this review, we outline a number of recent advances in our understanding of the pathogenesis of IgG4-RD, divided according to acquired immunology and innate immunology and other topics. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1560268DOI Listing
March 2019
11 Reads

Measuring disease activity and response to treatment in rheumatoid arthritis.

Expert Rev Clin Immunol 2018 Dec 17. Epub 2018 Dec 17.

b Department of Musculoskeletal Biology , Institute of Ageing and Chronic Disease, University of Liverpool, Clinical Sciences Centre, Aintree University Hospital , Liverpool.

Introduction: Effective treatment of rheumatoid arthritis (RA) requires suppression of the underlying inflammation. Measurement of such inflammation, the disease activity, is mandatory to target treatment and maximize outcomes. However, this is not as straightforward as it may seem. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1559050DOI Listing
December 2018
7 Reads

Allergen immunotherapy for food allergy from the Asian perspective: key challenges and opportunities.

Expert Rev Clin Immunol 2018 Nov 29. Epub 2018 Nov 29.

a Department of Paediatrics , The Chinese University of Hong Kong, , Prince of Wales Hospital Shatin , New Territories , Hong Kong.

Introduction: Prevalence of food allergy is rising in different regions of the world. Asia has not been spared from this epidemic, but epidemiological data have revealed a different pattern of food allergens in this continent. Allergen-specific immunotherapy (AIT) for food allergy (FA), which has been revolutionary as the main focus of research in recent years, needs to be adapted for the different populations in Asia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1554432DOI Listing
November 2018
9 Reads

Cytokines: the yin and yang of vitiligo pathogenesis.

Expert Rev Clin Immunol 2019 Feb 30;15(2):177-188. Epub 2018 Nov 30.

a Department of Biochemistry, Faculty of Science , The Maharaja Sayajirao University of Baroda , Vadodara , India.

Introduction: Dysregulation of melanocyte function is associated with vitiligo, an idiopathic autoimmune hypopigmentary skin disorder, caused by the selective destruction of melanocytes. Cytokines, the key mediators of immune response, which are pivotal in maintaining immune homeostasis, are crucial in vitiligo pathogenesis. Several studies indicate that there is an imbalance between pro- and anti-inflammatory cytokines in the skin and serum of vitiligo patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1550358DOI Listing
February 2019
8 Reads

Risks associated with use of TNF inhibitors in children with rheumatic diseases.

Expert Rev Clin Immunol 2018 Nov 19:1-10. Epub 2018 Nov 19.

e Department of Neurosciences, Psychology, Drug Research and Child Health, Rheumatology Unit, Meyer Children's Hospital , University of Florence , Florence , Italy.

Introduction: Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine involved in the pathogenesis of many inflammatory diseases. Several drugs blocking TNF-α are employed in clinical practice in pediatrics. Given their action on the immune system, TNF-α inhibitors have raised concerns on their safety profile since their introduction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1550359DOI Listing
November 2018
11 Reads

Characterization of autoantibodies in primary membranous nephropathy and their clinical significance.

Expert Rev Clin Immunol 2018 Nov 15:1-11. Epub 2018 Nov 15.

a III. Department of Medicine , University Medical Center Hamburg-Eppendorf , Hamburg , Germany.

Introduction: Membranous nephropathy (MN) is the most common cause of a nephrotic syndrome in Caucasian adults. The identification of target antigens in MN in the last decade has had a major impact on the clinical approach to these patients. Areas covered: Since the discoveries in animal models in the 1980s that circulating autoantibodies induce disease upon in situ binding to glomerular podocytes, many attempts have been undertaken to define the human antigens responsible for disease induction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1548934DOI Listing
November 2018
9 Reads

There is limited existing evidence to support the common assumption that strenuous endurance exercise bouts impair immune competency.

Expert Rev Clin Immunol 2018 Nov 15. Epub 2018 Nov 15.

a Department for Health , University of Bath , Bath , United Kingdom .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1548933DOI Listing
November 2018
15 Reads

Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts.

Expert Rev Clin Immunol 2018 Nov 9. Epub 2018 Nov 9.

a Institute of Clinical Chemistry and Laboratory Medicine , University Medical Center of the Johannes Gutenberg University , Mainz , Germany.

Introduction: Even though our understanding of the antiphospholipid syndrome (APS) has improved tremendously over the last decades, we are still not in a position to replace symptomatic anticoagulation by pathogenesis based causal treatments. Areas covered: Recent years have provided further insights into pathogenetically relevant mechanisms. These include a differentiation of pathogenic subtypes of antiphospholipid antibodies (aPL), novel mechanisms modulating disease activity, e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1546578DOI Listing
November 2018
7 Reads

Important risk factors for the development of food allergy and potential options for prevention.

Expert Rev Clin Immunol 2018 Nov 9:1-6. Epub 2018 Nov 9.

a Murdoch Children's Research Institute , Parkville , Australia.

Introduction: Food allergy currently affects up to 10% of infants. Identification and implementation of effective food allergy prevention strategies is thus imperative. Areas covered: We focus on five food allergy risk factors/prevention strategies which have been or are currently being tested in randomized controlled trials: (1) timely introduction of allergenic foods into the infant diet; (2) maternal diet and consumption of allergenic foods during pregnancy and breastfeeding; (3) infant skin barrier and the role of moisturizers in early life; (4) infant Vitamin D levels and the role of Vitamin D supplementation; and (5) microbial exposure in early life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1546577DOI Listing
November 2018
3 Reads

Growth failure in Crohn's disease children: may the first treatment have a role?

Expert Rev Clin Immunol 2018 Nov 7:1-8. Epub 2018 Nov 7.

a Artificial Nutrition Unit , "Bambino Gesù" Children Hospital , Rome , Italy.

Introduction: Growth failure in children is a frequent feature of childhood-onset Crohn's disease (CD), and stunting can persist into adulthood. Growth is an important outcome by which to judge the effectiveness of therapies in children; currently available studies in CD children have focused on the short-term impact of treatments on growth, and there are limited data regarding the long-term effects of treatments upon growth. Areas covered: We designed the present article to review whether the first treatment performed in newly diagnosed CD children may have a role on the future growth course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1543590DOI Listing
November 2018
8 Reads

Tildrakizumab for the treatment of psoriasis.

Expert Rev Clin Immunol 2018 Nov 3:1-8. Epub 2018 Nov 3.

b Curtin Medical School , Curtin University , Perth , Australia.

Introduction: Psoriasis is an immune-mediated skin disease amenable to targeted immunotherapy. Tildrakizumab is a humanized IgG1 monoclonal antibody targeting interleukin-23 p19 and is approved for use in moderate to severe psoriasis. Areas covered: This article reviews the mechanism of action, pharmacokinetics, safety, tolerability, and clinical efficacy of tildrakizumab, administered subcutaneously every 12 weeks, in treatment of moderate to severe psoriasis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1544493DOI Listing
November 2018
18 Reads

Pathophysiology of eosinophilic esophagitis: recent advances and their clinical implications.

Expert Rev Clin Immunol 2018 Nov 3:1-13. Epub 2018 Nov 3.

a Division of Allergy & Immunology , Children's Hospital of Philadelphia , Philadelphia , PA , USA.

Introduction: Diagnostic and therapeutic strategies in eosinophilic esophagitis (EoE) are evolving. New knowledge regarding the pathophysiology of EoE has been the foundation for updated diagnostic recommendations and new therapeutic trials. Areas covered: We performed structured literature searches in Medline and PubMed, Cochrane meta-analyses, and abstracts of international congresses to review therapeutic approaches for EoE in July 2018. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1544893DOI Listing
November 2018
16 Reads

Upadacitinib for the treatment of rheumatoid arthritis.

Expert Rev Clin Immunol 2018 Nov 3:1-13. Epub 2018 Nov 3.

b Department of Rheumatology and NIHR Clinical Research Facility , University Hospital Southampton NHS Foundation Trust , Southampton , UK.

Introduction: Tofacitinib and baricitinib have recently been approved as second-line treatments for Rheumatoid arthritis (RA) though their maximum expected efficacy may be limited by dose-related toxicities. Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects. Areas covered: In this paper, we review a newly developed oral selective JAK inhibitor, upadacitinib for the treatment of RA. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1544892DOI Listing
November 2018
16 Reads

Platelets: a potential target for rheumatoid arthritis treatment?

Expert Rev Clin Immunol 2018 Nov 5:1-3. Epub 2018 Nov 5.

a Section of Rheumatology, Department of Medicine , University of Perugia , Perugia , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1544071DOI Listing
November 2018
1 Read

Clinical profiles and risk assessment in patients with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Jan 13;15(1):73-81. Epub 2018 Nov 13.

a Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine , Hokkaido University , Sapporo , Japan.

Introduction: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to recent studies, not only APS patients but also incidentally-identified, asymptomatic aPL carriers are able to be stratified in terms of the risk of future thrombotic events, according to the variety and the titer of positive aPL tests and to the non-thrombotic, aPL-associated clinical manifestations. Areas covered: Here, we critically review (1) criteria manifestations of APS, (2) non-criteria manifestations of APS, (3) risk assessment in patients with APS and in aPL carriers, and (4) the potential role of primary thrombosis prophylaxis in aPL carriers. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1543025DOI Listing
January 2019
3 Reads

The relationship between smoking, psoriasis and psoriatic arthritis.

Expert Rev Clin Immunol 2018 Oct 31:1-8. Epub 2018 Oct 31.

a Study Centre of the Italian Group for Epidemiologic Research in Dermatology (GISED) , Bergamo , Italy.

Introduction: Smoking is the single most important cause of preventable mortality worldwide. Besides being associated with major cardiovascular and bronchopulmonary diseases, and several cancers, it has been linked with a number of immune-related conditions, including psoriasis and psoriatic arthritis (PsA) We aimed to summarize data on the role of smoking in the development and prognosis of psoriasis and PsA, pointing to the consequences in terms of disease management. Areas covered: Mechanisms, clinical manifestations, and comorbidities associated with smoking in psoriasis and PsA were reviewed by searching Medline, Embase and Cochrane Library databases for papers published between January 2000 and July 2018 using combination of terms. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1543591DOI Listing
October 2018
3 Reads

Post-viral atopic airway disease: pathogenesis and potential avenues for intervention.

Expert Rev Clin Immunol 2018 Oct 27:1-10. Epub 2018 Oct 27.

a Division of Allergy and Immunology , Nationwide Children's Hospital - The Ohio State University College of Medicine , Columbus , OH , USA.

Introduction: In early childhood, wheezing due to lower respiratory tract illness is often associated with infection by commonly known respiratory viruses such as respiratory syncytial virus (RSV) and human rhinovirus (RV). How respiratory viral infections lead to wheeze and/or asthma is an area of active research. Areas covered: This review provides an updated summary of the published information on the development of post-viral induced atopy and asthma and the mechanisms involved. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1541737DOI Listing
October 2018
15 Reads

Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies.

Expert Rev Clin Immunol 2018 Oct 27:1-13. Epub 2018 Oct 27.

a Rhinology Section, Specialist Allergy and Clinical Immunology , Royal National Throat Nose and Ear Hospital London and University College London Hospital NHS Foundation Trust, University College London , London , UK.

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex disease of the upper airway, with long-term morbidity. With detailed mechanistic studies currently lacking, understanding of the immunopathogenesis is still limited. However, outcomes from CRSwNP clinical studies using biologics that block key mediators or cells may provide some insights into how immune signaling pathways potentially integrate and modulate each other and contribute to disease. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1541738DOI Listing
October 2018
17 Reads

Use of synthetic and biologic DMARDs during pregnancy.

Expert Rev Clin Immunol 2018 Oct 26:1-13. Epub 2018 Oct 26.

e Global Medical Expert , GlaxoSmithKline (GSK) , Upper Providence , PA , USA.

Introduction: Since most of the autoimmune diseases (AID) affect mostly women in their fertile years, and fertility is in general preserved, the use of disease-modifying antirheumatic drugs (DMARDs) during conception, pregnancy, and lactation has been a matter of concern in the treatment of women affected by AID. Areas covered: We performed a comprehensive review of the latest and most relevant research papers published in the field and discussed different aspects related to the use of synthetic and biologic DMARDs and immunosuppressants in the preconceptional period, during pregnancy and lactation in AID patients, both in males and females. Expert commentary: Active AID impose an increased risk for adverse maternal and fetal outcomes, such as preeclampsia, miscarriage, intrauterine growth restriction, prematurity, low birth weight, and stillbirth. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1541739DOI Listing
October 2018
25 Reads

A review of ixekizumab in the treatment of psoriatic arthritis.

Expert Rev Clin Immunol 2018 Dec 5;14(12):993-1002. Epub 2018 Nov 5.

a Faculty of Medicine , Memorial University of Newfoundland , St. John's , Newfoundland and Labrador , Canada.

Introduction: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disorder with articular, peri-articular, and extra-articular features along with selected co-morbidities as a sequela to chronic inflammation. There is accumulating evidence that the Th-17 signaling pathway is of critical importance in PsA pathogenesis. Areas covered: Ixekizumab (IXE) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody directed against IL-17A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2018.1540931DOI Listing
December 2018
2 Reads